Ulinastatin |
Catalog No.GC19805
One-Click Copy Product Info
|
Ulinastatin is a broad‑spectrum protease inhibitor that suppresses the activity of various hydrolases, including trypsin, chymotrypsin, and elastase.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 80449-31-6
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Ulinastatin is a broad‑spectrum protease inhibitor that suppresses the activity of various hydrolases, including trypsin, chymotrypsin, and elastase[1-2]. Ulinastatin mitigates tissue injury and excessive inflammatory responses through stabilization of lysosomal membranes, inhibition of inflammatory mediator release, scavenging of oxygen free radicals, and modulation of immune reactions. Ulinastatin is indicated for the treatment of acute pancreatitis, acute exacerbations of chronic recurrent pancreatitis, and as adjunctive therapy in acute circulatory failure (e.g., septic shock, traumatic shock)[3-4].
In vitro, pretreatment of SH‑SY5Y cells and NGF‑differentiated PC12 cells with Ulinastatin (100‑500μM) for 6 hours, followed by incubation in an MPP⁺ (100μM)‑induced Parkinson’s disease cell model for 24 hours, Ulinastatin significantly suppressed MPP⁺‑induced NLRP3 inflammasome activation, reduced lactate dehydrogenase release and apoptosis, and enhanced dopamine secretion and tyrosine hydroxylase expression[5]. In an LPS (1μg/mL)‑induced acute kidney injury model using podocytes (MPC5), treatment with Ulinastatin (100U/mL) for 48 hours, Ulinastatin markedly inhibited LPS‑induced ferroptosis, upregulated SLC7A11 and GPX4 protein expression, promoted cell proliferation, and improved cytoskeletal structure[6].
In vivo, intraperitoneal pretreatment of adolescent mice with Ulinastatin (50000U/kg, once daily) for 7 days prior to repetitive ketamine exposure (30mg/kg, three times daily at 30‑minute intervals, for 7 days), Ulinastatin significantly decreased escape latency and increased platform‑crossing counts in the Morris water maze test and alleviated anxiety‑like behaviors in the open‑field test. Ulinastatin also reduced hippocampal levels of IL‑1β and IL‑6 inflammatory cytokines, as well as the expression of Tau, Tau‑pS396, and Aβ proteins[7]. In aged (18‑month‑old) rats undergoing tibial fracture fixation under sevoflurane anesthesia, a single intraperitoneal dose of Ulinastatin (100000U/kg, administered 30 minutes before surgery), Ulinastatin significantly increased spontaneous alternation rates in the Y‑maze and discrimination indices in the novel object recognition test. Moreover, Ulinastatin downregulated hippocampal TRPM4 channel expression, reduced neuronal apoptosis, and improved mitochondrial structure[8].
References:
[1] Luo Q, Tang Y, Jiang Z, et al. hUCMSCs reduce theca interstitial cells apoptosis and restore ovarian function in premature ovarian insufficiency rats through regulating NR4A1-mediated mitochondrial mechanisms. Reprod Biol Endocrinol. 2022 Aug 19;20(1):125.
[2] Lv ZT, Huang JM, Zhang JM, et al. Effect of Ulinastatin in the Treatment of Postperative Cognitive Dysfunction: Review of Current Literature. Biomed Res Int. 2016;2016:2571080.
[3] Lv B, Jiang XM, Wang DW, et al. Protective Effects and Mechanisms of Action of Ulinastatin against Cerebral Ischemia-Reperfusion Injury. Curr Pharm Des. 2020;26(27):3332-3340.
[4] Atal SS, Atal S. Ulinastatin - a newer potential therapeutic option for multiple organ dysfunction syndrome. J Basic Clin Physiol Pharmacol. 2016 Mar;27(2):91-9.
[5] Lin Y, Xu D, Gao F, et al. Ulinastatin inhibits NLRP3-induced apoptosis in a PD cell model. Ann Transl Med. 2021 Jun;9(11):924.
[6] Yang X, Guo N. Ulinastatin ameliorates podocyte ferroptosis via regulating miR-144-3p/SLC7A11 axis in acute kidney injury. In Vitro Cell Dev Biol Anim. 2023 Oct;59(9):697-705.
[7] Hong Y, Meng S, Wang S, et al. Ulinastatin Alleviates Repetitive Ketamine Exposure-Evoked Cognitive Impairment in Adolescent Mice. Neural Plast. 2022 Dec 12;2022:6168284.
[8] Xia X, Li J, Zhang M, et al. Ulinastatin modulates TRPM4 expression and apoptosis to mitigate cognitive dysfunction in aged perioperative neurocognitive disorder rats. Sci Rep. 2025 May 22;15(1):17774.
| Cell experiment [1]: | |
|
Cell lines |
SH-SY5Y cells (human neuroblastoma cell line) and PC12 cells (rat adrenal pheochromocytoma cell line) |
|
Preparation Method |
SH-SY5Y cells were cultured in DMEM supplemented with 10% FBS. PC12 cells were maintained in RPMI-1640 medium with 5% FBS and differentiated using nerve growth factor (NGF; 50ng/mL) for 4 days. Cells were pretreated with Ulinastatin (100–500μM) for 6 hours, followed by exposure to MPP⁺ (100μM) for 24 hours to establish a Parkinson’s disease (PD) model. |
|
Reaction Conditions |
100–500μM; pretreatment for 6h |
|
Applications |
Ulinastatin significantly attenuated MPP⁺-induced cytotoxicity by enhancing cell viability and reducing lactate dehydrogenase (LDH) release. Ulinastatin suppressed apoptosis and inhibited the secretion of pro-inflammatory cytokines. Ulinastatin also restored dopamine (DA) secretion (HPLC) and tyrosine hydroxylase (TH) expression in MPP⁺-treated cells. Mechanistically, Ulinastatin downregulated the NLRP3 pathway, reducing the expression of NLRP3, caspase-1, ASC, IL-1β, and IL-18. The protective effects were reversed by the NLRP3 activator Nigericin, confirming NLRP3 inhibition as a key mechanism. |
| Animal experiment [2]: | |
|
Animal models |
21-day-old male C57BL/6 mice |
|
Preparation Method |
Mice in the chronic Ketamine (CK) group were intraperitoneally injected with ketamine (30mg/kg) three times daily (30-minute intervals) for 7 consecutive days. Mice in the Ulinastatin pretreatment group received Ulinastatin (50000U/kg) intraperitoneally 30 minutes before the first Ketamine injection each day. |
|
Dosage form |
50000U/kg; i.p.; once daily for 7 days |
|
Applications |
Repetitive Ketamine exposure induced cognitive impairment and anxiety-like behaviors. Ulinastatin pretreatment significantly improved cognitive performance, as evidenced by shorter escape latency and increased platform-crossing times in the MWM test, and alleviated anxiety-like behaviors by increasing center duration time in the OFT. Ulinastatin also suppressed neuroinflammation by reducing hippocampal levels of IL-1β and IL-6. Furthermore, Ulinastatin downregulated the expression of dementia-related proteins, including Tau, phosphorylated Tau (pS396), and Aβ, in the hippocampus. |
|
References: |
|
| Cas No. | 80449-31-6 | SDF | |
| Formula | M.Wt | ||
| Solubility | H2O : 10 mg/mL (Need ultrasonic); DMSO : 1 mg/mL (Need ultrasonic) | Storage | -20°C, protect from light |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
-
Potency:2807 U/mg solid Appearance: A solid
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 40 reference(s) in Google Scholar.)